US FDA warns surgeries over inappropriate advertising of Allergan's Lap-Band
This article was originally published in Clinica
Executive Summary
The US FDA has sent warning letters to several US institutions over misleading advertising of Allergan's gastric band Lap-Band. The letters, which went to eight surgical centres in California and the marketing firm 1-800-GET-THIN, said that their adverts for Lap-Band failed to provide required information on the risks and possible side-effects of the product. The FDA is also concerned that the font size of risk information on the advertising inserts is "too small to be read by customers".